Telomerase activation is critical for the immortalization of primary human keratinocytes by the high-risk HPV E6 and E7 oncoproteins, and this activation is mediated in part by E6-induction of the hTERT promoter. E6 induces the hTERT promoter via interactions with the cellular ubiquitin ligase, E6AP, and with the c-Myc and NFX-1 proteins, which are resident on the promoter. In the current study we demonstrate that E6 protein interacts directly with the hTERT protein. Correlating with its ability to bind hTERT, E6 also associates with telomeric DNA and with endogenous active telomerase complexes. Most importantly, E6 increases the telomerase activity of human foreskin fibroblasts transduced with the hTERT gene, and this activity is independent of hTERT mRNA expression. Unlike its ability to degrade p53, E6 does not degrade hTERT protein in vitro or in vivo. Our studies of E6/hTERT interactions also reveal that the C-terminal tagged hTERT protein, although incapable of immortalizing fibroblasts, does immortalize keratinocytes in collaboration with the viral E7 protein. Thus, E6 protein mediates telomerase activation by a posttranscriptional mechanism and these findings provide a model for exploring the direct modulation of cell telomerase/telomere function by an oncogenic virus and suggest its potential role in both neoplasia and virus replication.cell immortalization ͉ hTERT ͉ oncoproteins ͉ papillomavirus T he HPV-16 E6 oncoprotein increases cellular telomerase activity, predominantly by inducing transcription of the hTERT gene (1-6). The hTERT protein is the catalytic, ratelimiting subunit of the telomerase enzyme complex and is selectively expressed in a small subset of normal cells (stem cells), tumor tissues, and tumor-derived cell lines (7-10). Interestingly, overexpression of hTERT or c-Myc (which transactivates the hTERT promoter) can substitute for E6 in the immortalization of primary HFKs, indicating that telomerase activation constitutes a major immortalizing function of E6 (11,12). Our previous studies and those of other laboratories indicate that E6-mediated hTERT transactivation is independent of its ability to degrade p53 or interact with PDZ proteins (11-16). However, hTERT transactivation by E6 is dependent upon its binding the cellular ubiquitin ligase, E6AP (13,14,(17)(18)(19)(20). There appear to be two critical targets for E6/E6AP on the hTERT promoter, Myc (12, 15, 16) and NFX-1 (13, 18, 21), which transactivate and transrepress the promoter respectively. The model for E6 regulation of the hTERT promoter is likely to be quite complex and it is anticipated that there might be additional targets for E6 on this promoter.In addition to activating telomerase, E6 interacts with a spectrum of cellular proteins that may contribute to HPV oncogenicity. For example, E6 binds proteins that regulate cell differentiation, adhesion, polarity, proliferation, apoptosis, gene transcription, and chromosomal stability (22,23). E6 interacts with these target proteins via several mechanisms, including two known ...

The progesterone receptor (PR) plays roles in normal mammary development and breast cancer formation, where it may exert both stimulatory and inhibitory actions. Previously, the breast cancer susceptibility gene product BRCA1 was found to interact with and inhibit the transcriptional activity of estrogen receptor-alpha. In this study, we found that exogenous wild-type BRCA1 inhibited the activity of the PR in transient transfection assays utilizing a mouse mammary tumor virus-Luc reporter. Wild-type BRCA1 inhibited the activity of endogenous PR in human breast cancer cells (T47D and MCF-7) and inhibited the activity of exogenous PR-A, PR-B, and [PR-A plus PR-B] isoforms. On the other hand, knockdown of endogenous BRCA1 using small interfering RNA enhanced the progesterone-stimulated activity of the PR by about 4-fold. We documented an in vivo association of the endogenous BRCA1 with PR isoforms A and B and a direct in vitro interaction between BRCA1 and PR, which was partially mapped. Whereas down-regulation of the coactivator p300 contributes to the BRCA1-mediated repression of estrogen receptor-alpha, this mechanism does not contribute to inhibition of PR activity, because exogenous p300 did not rescue the BRCA1 repression of PR activity. The BRCA1-PR interaction has functional consequences. Thus, we showed that BRCA1 inhibits the expression of various endogenous progesterone-responsive genes and inhibits progesterone-stimulated proliferation of T47D cells. Finally, exogenous progesterone caused an exaggerated proliferative response in the mammary glands of mice harboring a mammary-targeted conditional deletion of the full-length isoform of Brca1. These findings suggest that BRCA1 regulates the activity of progesterone, a major hormone of pregnancy that may also participate in mammary carcinogenesis.

The E6 and E7 proteins of high-risk HPVs are both required for the immortalization of primary human keratinocytes and the maintenance of the malignant phenotype of HPV-positive cancer cell lines. Our previous studies have shown that E6 protein binds Myc protein and that both E6 and Myc associate with and cooperatively activate the hTERT promoter, thereby increasing cellular telomerase activity. In this study, we evaluated the role of E7 in the maintenance and activation of telomerase in immortalized and tumorigenic cells. siRNA knockdown of either E6 or E7 (or both) in HPV-immortalized cells or an HPV-positive cancer cell line reduced hTERT transcription and telomerase activity. Since telomerase was inhibited by E7 siRNA in cells that independently expressed the E6 and E7 genes, our results reveal an independent role for E7 in the maintenance of telomerase activity. However, E7 alone was insufficient to increase endogenous hTERT mRNA or telomerase activity, although it significantly augmented E6-induced hTERT transcription and telomerase activity. To further explore this apparent E7-induced promoter augmentation, we analyzed an exogenous hTERT core promoter in transduced keratinocytes. E7 alone induced the wt hTERT promoter and augmented E6-induced hTERT promoter activity. Mutation of the E2F site in the hTERT promoter abrogated the ability of E7 to induce the hTERT promoter or to enhance the ability of E6 to induce the promoter. Correspondingly, keratinocytes expressing E6 and a mutant E7 (defective for binding pRb pocket proteins) showed lower telomerase activity than cells expressing wt E6 and wt E7. Thus, HPV E7 plays a role in the maintenance of telomerase activity in stable cell lines and augments acute, E6-induced hTERT promoter activity.

Although fluorescent indicators have been broadly utilized for monitoring bioactivities, fluorescence imaging, when applied to mammals, is limited to superficial targets or requires invasive surgical procedures. Thus, there is emerging interest in developing bioluminescent indicators for noninvasive mammalian imaging. Bioluminescence imaging (BLI) of neuronal activity is highly desired but hindered by insufficient photons needed to digitalize fast brain activities. In this work, we develop a luciferase prosubstrate deliverable at an increased dose and activated in vivo by nonspecific esterase. We further engineer a bright, bioluminescent indicator with robust responsiveness to calcium ions (Ca2+) and appreciable emission above 600 nm. Integration of these advantageous components enables the imaging of the activity of neuronal ensembles in awake mice minimally invasively with excellent signal-to-background and subsecond temporal resolution. This study thus establishes a paradigm for studying brain function in health and disease.

Previously, we reported that BRCA1 strongly represses the transcriptional activity of estrogen receptor-␣ (ER-␣) in human breast and prostate cancer cells but only weakly inhibits ER-␣ in cervical cancer cells. We now report that introduction of the human papillomavirus E7 or E6 oncogenes into human papillomavirus-negative cells rescues the BRCA1 repression of ER-␣ activity and that the E7 and E6 oncoproteins interact directly with BRCA1 in vitro and associate with BRCA1 in vivo in cultured cells. This interaction involves at least two contact points on BRCA1, one within an N-terminal site shown previously to interact with ER-␣ and the other in a C-terminal region of BRCA1 containing the first BRCA1 C-terminal domain. Point mutations within the zinc finger domains of E7 and E6 inactivated the binding to the N terminus of BRCA1 and reduced their ability to rescue BRCA1 inhibition of ER-␣. E6 and E7 also antagonized the ability of BRCA1 to inhibit c-Myc E-box-mediated transactivation and human telomerase reverse transcriptase promoter activity, in a manner dependent upon the zinc finger domains. Finally, the ability of E6 and E7 to antagonize BRCA1 did not involve proteolytic degradation of BRCA1. These findings suggest functional interactions of BRCA1 with E7 and E6. The potential significance of these findings is discussed.Mutations of the breast cancer susceptibility gene 1 (BRCA1) 2 (chromosome 17q21) are linked to a high risk for breast and ovarian cancers in hereditary early onset breast and breast-ovarian cancer families (1, 2). These mutations also confer and increased risk for these cancer types in Ashkenazi Jewish women unselected for a family history of cancer (3). A large study of cancer risk in BRCA1 cancer families in Europe and North America revealed that BRCA1 mutation carriers are also at significantly increased risk for the development of several other cancer types, including pancreatic cancer, uterine cancer, cervical cancer, and prostate cancer (in men younger than age 65) (4). For cervical cancer, the relative risk of BRCA1 mutation carriers compared with noncarriers was 3.72 (95% confidence interval ϭ 2.26 -6.10, p Ͻ 0.001, two-sided test). A subset of patients with sporadic invasive cervical cancer shows hypermethylation of the BRCA1 promoter (5), as do patients with sporadic breast and ovarian cancers (6, 7). BRCA1 promoter methylation may predict a worse prognosis in cervical cancer (8), although this point requires further study. An earlier and smaller study of cancer incidence in the relatives of BRCA1 and BRCA2 mutation carriers revealed about a 4-fold increased risk of cervical cancer in BRCA2-associated families, although the risk in BRCA1 families was not similarly elevated (9). Most interestingly, loss of heterozygosity at chromosome 17q, a site that contains the BRCA1 gene, appears to be a common event in cervical cancer (10).Previously, we found that the overexpression of BRCA1 inhibits the estrogen (E 2 )-induced transcriptional activity of the estrogen receptor-␣ (ER-␣) and inhi...